Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome–Coronavirus 2 In Vitro When Administered After Virus Infection. (19th June 2020)

• Record Type: Journal Article
• Authors: Clementi, Nicola; Ferrarese, Roberto; Criscuolo, Elena; Diotti, Roberta Antonia; Castelli, Matteo; Scagnolari, Carolina; Burioni, Roberto; Antonelli, Guido; Clementi, Massimo; Mancini, Nicasio
• Is Part Of: Journal of infectious diseases. Volume 222:Number 5(2020)
• Page Start: 722
• Page End: 725
• Publication Date: 2020-06-19
• Subjects: SARS-CoV-2 -- IFN-β-1a -- COVID-19 clinical trial; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiaa350
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: The ongoing coronavirus disease 2019 pandemic has forced the clinical and scientific community to try drug repurposing of existing antiviral agents as a quick option against severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2). Under this scenario, interferon (IFN) β-1a, whose antiviral potential is already known, and which is a drug currently used in the clinical management of multiple sclerosis, may represent as a potential candidate. In this report, we demonstrate that IFN-β-1a was highly effective in inhibiting in vitro SARS-CoV-2 replication at clinically achievable concentration when administered after virus infection. Abstract : Interferon β-1a hampers severe acute respiratory syndrome–coronavirus 2 replication in a Vero E6 infection model when administered after virus infection in a dose-dependent manner. This observation could be useful in the set-up of clinical trials.